Effect of topiramate on apoptosis-related protein expression of hippocampus in model rats with Alzheimers Disease

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 6, 2014, Pages 761-768

  Cheng, X L ^a   Li, M K ^a  

^a YANGTZE UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Bax; Bcl 2; Caspase 3; Fas; Survivin; Topiramate

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; CASPASE 3; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; TOPIRAMATE; AMYLOID BETA PROTEIN; APOPTOSIS REGULATORY PROTEIN; BIRC5 PROTEIN, RAT; FRUCTOSE; MICROTUBULE ASSOCIATED PROTEIN; PEPTIDE FRAGMENT; TNFRSF6 PROTEIN, RAT;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN SLICE; CELL DENSITY; COGNITION; CONTROLLED STUDY; HIPPOCAMPUS; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MORRIS WATER MAZE TEST; NERVE CELL; NONHUMAN; OPTICAL DENSITY; PROTEIN EXPRESSION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; DISEASE MODELS, ANIMAL; FRUCTOSE; HIPPOCAMPUS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR;

EID: 84902086705     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. QUERFURTH HW, LAFERLA FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
2. DAVIES CA, MANN DM, SUMPTER PQ, YATES PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151-164.
3. SELKOE DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
4. MASLIAH E, MALLORY M, ALFORD M, DETERESA R, HANSEN LA, MCKEEL DW, MORRIS JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56: 127-129.
5. TERRY RD, MASLIAH E, SALMON DP, BUTTERS N, DETERESA R, HILL R, HANSEN LA, KATZMAN R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
6. BAMBERGER ME, LANDRETH GE. Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist 2002; 8: 276-283.
7. CASTELLANI RJ, ROLSTON RK, SMITH MA. Alzheimer disease. Dis Mon 2010; 56: 484-546.
8. BUTTERFIELD DA, GRIFFIN S, MUNCH G, PASINETTI GM. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis 2002; 4: 193-201.
9. CUMMINGS JL. Alzheimer's disease: from molecular biology to neuropsychiatry. Semin Clin Neuropsychiatry 2003; 8: 31-36.
10. CALISSANO P, MATRONE C, AMADORO G. Apoptos is and in vitro Alzheimer disease neuronal models. Commun Integr Biol 2009; 2: 163-169.
11. DE KOSKY ST. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc 2003; 51(Suppl 1): 314-320.
12. DORAISWAMY PM. Alzheimer's disease and the glutamate NMDA receptor. Psychopharmacol Bull 2003; 37: 41-49.
13. DORAISWAMY PM. The role of the N-methyl-Daspartate receptor in Alzheimer's disease: therapeutic potential. Curr Neurol Neurosci Rep 2003; 3: 373-378.
14. SASTRE M, WALTER J, GENTLEMAN SM. Interactions between APP secretases and inflammatory mediators. J Neuroinflamm 2008; 5: 25.
15. LI LX, DAI JP, RU LQ, YIN GF, ZHAO B. Effects of tanshinone on neuropathological changes induced by amyloid beta-peptide(1-40) injection in rat hippocampus. Acta Pharmacol Sin 2004; 25: 861-868.
16. LAFERLA FM, TINKLE BT, BIEBERICH CJ, HAUDENSCHILD CC, JAY G. The Alzheimer's Abeta peptide induces neurogegeneration and apoptotic cell death in transgenic mice. Nat Genet 1995; 9: 12-30.
17. SU JH, ANDERSON AJ, CUMMINGS BJ, COTMAN CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994; 5: 2529-2533.
18. CALISSANO P, MATRONE C, AMADORO G. Apoptosis and in vitro Alzheimer disease neuronal models. Commun Integr Biol 2009; 2: 163-169.
19. YANG Y, VARVEL NH, LAMB BT, HERRUP K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci 2006; 26: 775-784.
20. NEVER RL, MCPHIE DL. Dysfunction of amy oid precursor protein signaling in neurons leads to DNA synthesis and apoptosis. Biochim Biophys Acta 2007; 1772: 430-437.
21. BISAGLIA M, VENEZIA V, PICCIOLI P, STANZIONE S, PORCILE C, RUSSO C, MANCINI F, MILANESE C, SCHETTINI G. Acetaminophen protects hippoeampal neurols and PCI2 cultures from amyloid beta-peptides induced oxidative stress and reduces NF-kappaB activation. Neurochem Int 2002; 41: 43-54.
22. HARDY J, SCLKOO DJ. The amyloid hypothesis of Alzheimer' B disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
23. GALINDO MF, IKUTA I, ZHU X, CASADESUS G, JORDÁN J. Mitochondrial biology in Alzheimer's disease pathngenesis. J Neurochem 2010; 114: 933-945.
24. BUENZ EJ, SAUER BM, LAFRANCE-COREY RG, DEB C, DENIC A, GERMAN CL, HOWE CL. Apoptosis of hippocampal pyramidal neurons is virus independent in a in a mouse model of acute neurovirulent picornavirus infection. Am J Pathol 2009; 175: 668-684.
25. BROUGHTON BR, REUTENS DC, SOBEY CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009; 40: 331-339.
26. CHEN Y, MCPHIE DL, HIRSCHBERG J, NEVE RL. The amyloid precursor protein-binding protein APPBPI drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem 2000; 275: 8929-8935.
27. SHAKED GM, KUMMER MP, LU DC, GALVAN V, BREDESEN DE, KOO EH. Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624). FASEB J 2006; 20: 1254-1256.
28. ROVELET LECRUX A, HANNEQUIN P, RANX G, LE MEUR N, LAQUERRIÈRE A, VITAL A, DUMANCHIN C, FEUILLETTE S, BRICE A, VERCELLETTO M, DUBAS F, FREBOURG T, CAMPION D. APP locus duplication cause autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38: 24-26.
29. KUO MH, ALLIS CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20: 615-626.
30. CYR AR, DOMANN FE. The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid Redox Signal 2011; 15: 551-589.
31. WADE PA, PRUSS D, WOLFFE AP. Histone acetylation: chromatin in action. Trends Biochem Sci 1997; 22: 128-132.
32. BANERJEE A, TRIVEDI CM, DAMERA G, JIANG M, JESTER W, HOSHI T, et al. Trichostatin A abrogates airway constriction, but not inflammation in mouse and human asthma models. Am J Respir Cell Mol Biol 2012; 46: 132-138.
33. CHOI JH, OH SW, KANG MS, KWON HJ, OH GT, KIM DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005; 35: 89-96.
34. ANTOS CL, MCKINSEY TA, DREITZ M, HOLLINGSWORTH LM, ZHANG CL, SCHREIBER K, RINDT H, GORCZYNSKI RJ, OLSON EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003; 278: 28930-28937.
35. BACKS J, OLSON EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006; 98: 15-24.
36. HABERLAND M, MONTGOMERY RL, OLSON EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32-42.
37. KONG Y, TANNOUS P, LU G, BERENJI K, ROTHERMEL BA, OLSON EN, HILL JA. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006; 113: 2579-2588.
38. MCKINSEY TA, OLSON EN. Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found Symp 2004; 259: 132-1341. discussion 141-145, 163-169.
39. CHUANG DM, LENG Y, MARINOVA Z, KIM HJ, CHIU CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009; 32: 591-601.
40. ROYCE SG, DANG W, VERVERIS K, DE SAMPAYO N, ELOSTA A, TANG MLK, KARAGGIANNIS TC. Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease. Epigenetics 2011; 6: 1463-1470.
41. FRANCIS YI, FA M, ASHRAF H, ZHANG H, STANISZEWSKI A, LATCHMAN DS, ARANCIO O. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 2009; 18: 131-139.
42. KILGORE M, MILLER CA, FASS DM, HENNIG KM, HAGGARTY SJ, SWEATT JD, RUMBAUGH G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010; 35: 870-880.
43. PARK HJ, KIM HJ, PARK HJ, RA J, ZHENG LT, YIM SV, CHUNG JH. Protective effect of topiramate on kainic acid-induced cell death in mice hippocampus. Epilepsia 2008; 49: 163-167.
44. SHI JQ, WANG BR, TIAN YY, XU J, GAO L, ZHAO SL, JIANG T, XIE HG, ZHANG YD. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther 2013; 19: 871-881.
45. MOWLA A, PANI A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 2010; 30: 40-43.
46. OHKAWARA T, NAGASE H, KOH CS, NAKAYAMA K. The amyloid precursor protein intracellular domain alaters gene expression and induces neuron-specific apoptosis. Gene 2011; 475: 1-9.
47. KURUL SH, YI U, KUMRAL A, TU YAN K, CILAKER S, KOLATAN E, YILMAZ O, GENÇ S. Protective effects of topiramate against hyperoxic brain injury in the developing brain. Neuropediatrics 2009; 40: 22-27.
48. EYAL S, YAGEN B, SOBOL E, ALTSCHULER Y, SHMUEL M, BIALER M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45: 737-744.
49. ZIEMANN U. Pharmacology of TMS. Suppl Clin Neurophysiol 2003; 56: 226-231.